AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Medical Journal of Peking Union Medical College Hospital Article
PDF (1.1 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Publishing Language: Chinese

Advances in Dynamic Monitoring of Immune Checkpoint Inhibitors as the Prognostic Markers for Advanced Non-small Cell Lung Cancer

Liyuan DAI1, Yuankai SHI2,3, Xiaohong HAN4,5( )
Department of Clinical Laboratory, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Cancer Center, National Clinical Research Center for Cancer, Beijing 100021, China
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Cancer Center, National Clinical Research Center for Cancer, Beijing 100021, China
Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Cancer Center, National Clinical Research Center for Cancer, Beijing 100021, China
Clinical Pharmacology Research Center, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
Show Author Information

Abstract

The use of immune checkpoint inhibitors(ICIs) in advanced non-small cell lung cancer(NSCLC) significantly improves survival, but it has clinical problems such as low response rate. Treatment of tumor with ICIs is a dynamic change that involves the process of tumor-immune system interaction. Vertical monitoring of dynamic changes of biomarkers is helpful to eliminate individual differences and to provide information on spatiotemporal heterogeneity of tumors. This paper reviews the biomarkers of advanced NSCLC, covering the aspects of treatment with ICIs from tumor cell origin, immune microenvironmental source and joint indicators.

Keywords

immunotherapynon-small cell lung cancerdynamic monitoringprognostic markerimmune checkpoint inhibitors
CLC number: R734.2; R730.3 Document code: A Article ID: 1674-9081(2022)02-0287-09

References

【1】
【1】
 
 
Crossref Google Scholar
Medical Journal of Peking Union Medical College Hospital
Volume 13 Issue 2,
March 2022
Pages 287-295
DOI: 10.12290/xhyxzz.2021-0608

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
DAI L, SHI Y, HAN X. Advances in Dynamic Monitoring of Immune Checkpoint Inhibitors as the Prognostic Markers for Advanced Non-small Cell Lung Cancer. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 287-295. https://doi.org/10.12290/xhyxzz.2021-0608

148

Views

1

Downloads

0

Crossref

2

Scopus

2

CSCD
Received: 22 August 2021
Accepted: 13 October 2021
Published: 14 March 2022
© 2024 Medical Journal of Peking Union Medical College Hospital